Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 10, 2005. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Executive Supplemental Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
Changes in share interests were reported for five individuals due to the re-investment of dividends paid on October 6, 2005. The transactions occurred at a price of $51.40 per share under the Annual Investment Plan feature.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification regarding insider trading rules (Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b)).
Important Facts for Investors
- Transaction Type: Increase in Ordinary Share ADR interests via dividend re-investment.
- Transaction Date: October 10, 2005 (Notification date); October 6, 2005 (Dividend payment date).
- Share Price: $51.40 per share.
- Individuals Notified: Mr. W Calhoun, Dr. J P Garnier, Mr. D Stout, Dr. T Yamada, and Mr. J Ziegler.
- Share Quantities: Specific share counts were listed in the source text (e.g., 267.303 for Mr. Calhoun), though the unit (shares vs. thousands) is not explicitly defined in the snippet.